These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31021010)

  • 21. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
    Bun S; Yunokawa M; Tamaki Y; Shimomura A; Shimoi T; Kodaira M; Shimizu C; Yonemori K; Fujiwara Y; Makino Y; Terakado H; Tamura K
    Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.
    Saini A; Berruti A; Sperone P; Bitossi R; Tampellini M; Dogliotti L; Gorzegno G
    Lancet Oncol; 2006 Feb; 7(2):186-7. PubMed ID: 16455484
    [No Abstract]   [Full Text] [Related]  

  • 24. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
    von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
    Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extravasation of pegylated-liposomal doxorubicin: favorable outcome after immediate subcutaneous administration of corticosteroids.
    Mitsuma A; Sawaki M; Shibata T; Morita S; Inada M; Shimokata T; Sugishita M; Kitagawa K; Sawada M; Nawa A; Ando Y
    Nagoya J Med Sci; 2012 Feb; 74(1-2):189-92. PubMed ID: 22515126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
    Vaccaro M; Santarpia M; Calapai G; Mannucci C; Borgia F; Altavilla G; Cannavò SP
    Br J Dermatol; 2017 Feb; 176(2):507-509. PubMed ID: 27291307
    [No Abstract]   [Full Text] [Related]  

  • 29. [Absence of cutaneous complications following extravasation of pegylated liposomal doxorubicin].
    Capitain O; Lortholary A
    Presse Med; 2003 Jun; 32(23):1077. PubMed ID: 12910162
    [No Abstract]   [Full Text] [Related]  

  • 30. Flagellate Pattern of Toxic Erythema of Chemotherapy Due to Doxorubicin: A Case Report.
    Vadeboncoeur S; Côté B
    J Cutan Med Surg; 2016 Sep; 20(5):481-3. PubMed ID: 27068228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
    Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
    Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Granular parakeratosis in a patient treated with liposomal doxorubicin for ovarian carcinoma.
    Jaconelli L; Doebelin B; Kanitakis J; Saïd BB; Faure M; Claudy A
    J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S84-7. PubMed ID: 18489055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intertriginous rash caused by pegylated liposomal doxorubicin].
    Monteagudo B; Afonso-Afonso FJ; Cabanillas M; Used-Aznar MM
    Actas Dermosifiliogr; 2009 Apr; 100(3):241-2. PubMed ID: 19457315
    [No Abstract]   [Full Text] [Related]  

  • 34. Palmar-plantar erythrodysaesthesia and non-pegylated liposomal doxorubicin. A case study.
    Tamayo-Orbegozo E; Iruin-Sanz A; Oñate-Muzás E; Segrelles-Bellmunt G
    Farm Hosp; 2011; 35(1):46-7. PubMed ID: 20619714
    [No Abstract]   [Full Text] [Related]  

  • 35. Delayed genital blisters following iodixanol administration.
    Zhang W; Yuan W; Yuan HL; Yang XL; Xie H
    Clin Toxicol (Phila); 2017 Sep; 55(8):939-940. PubMed ID: 28463024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
    Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
    Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment.
    Nomura H; Sakamoto K; Sugihara T; Okamoto S; Aoki Y; Tanigawa T; Matoda M; Omatsu K; Kanao H; Kato K; Utsugi K; Sugiyama Y; Takeshima N
    Medicine (Baltimore); 2018 Feb; 97(7):e9932. PubMed ID: 29443777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
    Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
    Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
    Von Moos R; Cathomas R
    Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.